{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:59:54Z","timestamp":1781711994913,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202937"],"award-info":[{"award-number":["82202937"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373517"],"award-info":[{"award-number":["82373517"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017633","name":"Shanghai Anti Cancer Association","doi-asserted-by":"publisher","award":["SHCY-JC-2023221"],"award-info":[{"award-number":["SHCY-JC-2023221"]}],"id":[{"id":"10.13039\/100017633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijrobp.2025.12.049","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:22:38Z","timestamp":1768004558000},"page":"1388-1398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stereotactic Body Radiation Therapy With Continued First-Line PD-1 Inhibitor-based Therapy as a Resistance-Overcoming Strategy in Oligoprogressive Hepatocellular Carcinoma: A Prospective Phase 2 Clinical Study"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4043-7779","authenticated-orcid":false,"given":"Shu-Jung","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Cheng","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Jun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Gang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Chong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7339-7083","authenticated-orcid":false,"given":"Shi-Suo","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.12.049_bib0001","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0002","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jhep.2020.08.010","article-title":"Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0003","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/cancers12041046","article-title":"Oligoprogressive non-small-cell lung cancer under treatment with PD-(L)1 inhibitors","volume":"12","author":"Rheinheimer","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0004","article-title":"Progression patterns, treatment, and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0005","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The dandelion dilemma revisited for oligoprogression: Treat the whole lawn or weed selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0006","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0007","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0008","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3390\/cancers17071233","article-title":"Treatment approaches for oligoprogressive non-small cell lung cancer: A review of ablative radiotherapy","volume":"17","author":"Gombrich","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0009","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S1470-2045(20)30328-4","article-title":"Treatment after progression in the era of immunotherapy","volume":"21","author":"Billan","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0010","article-title":"Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade","volume":"25","author":"Sindhu","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0011","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/liv.15502","article-title":"Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study","volume":"43","author":"Talbot","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0012","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/bjr\/tqae100","article-title":"Strategies for overcoming tumour resistance to immunotherapy: Harnessing the power of radiation therapy","volume":"97","author":"Passelli","year":"2024","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0013","article-title":"RECQL4 Inhibits radiation-induced tumor immune awakening via suppressing the cGAS-STING pathway in hepatocellular carcinoma","volume":"11","author":"Hong","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0014","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","article-title":"Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation","volume":"112","author":"Du","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0015","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2119055","article-title":"Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling","volume":"14","author":"Li","year":"2022","journal-title":"Gut Microbes"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110424","article-title":"Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors","volume":"199","author":"Wang","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0017","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.3390\/cancers14235848","article-title":"Stereotactic ablative radiotherapy for oligometastatic hepatocellular carcinoma: A multi-institutional retrospective study (KROG 20-04)","volume":"14","author":"Kim","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0018","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2024.03.003","article-title":"Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study","volume":"81","author":"Choi","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0019","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ijrobp.2024.09.022","article-title":"Comparison of metastasectomy and stereotactic body radiation therapy for pulmonary oligometastasis from hepatocellular carcinoma: A propensity score-weighted analysis","volume":"121","author":"Shin","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0020","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.3748\/wjg.v29.i24.3871","article-title":"Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial","volume":"29","author":"Chen","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0021","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/CM9.0000000000003124","article-title":"Radiotherapy enhances efficacy of PD-1 inhibitors in advanced hepatocellular carcinoma: A propensity-matched real-world study","volume":"137","author":"Hsu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0022","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.ijrobp.2023.07.001","article-title":"Radiation therapy with combination therapy of immune checkpoint inhibitors and antiangiogenic therapy for hepatocellular carcinoma","volume":"118","author":"Ning","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0023","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0024","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1158\/1078-0432.CCR-22-2592","article-title":"Efficacy and safety of stereotactic body radiotherapy combined with camrelizumab and apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus","volume":"29","author":"Hu","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijrobp.2011.11.058","article-title":"Stereotactic body radiation therapy in recurrent hepatocellular carcinoma","volume":"84","author":"Huang","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0026","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2018.12.013","article-title":"Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma","volume":"131","author":"Kim","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0027","unstructured":"Adapted from Radiation Therapy Oncology Group. RTOG 1112: Sorafenib tosylate with or without stereotactic body radiation therapy in treating patients with liver cancer. Accessed July 30, 2020. https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/rtog-1112?filter=rtog-1112"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0028","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000475768","article-title":"Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting","volume":"6","author":"Zeng","year":"2017","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0029","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001945","article-title":"Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors","volume":"9","author":"Wong","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0031","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1007\/s00432-022-04206-8","article-title":"Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: A multicenter retrospective study","volume":"149","author":"Roessler","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0032","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000512781","article-title":"Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational multicenter retrospective study","volume":"10","author":"Yoo","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0033","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijrobp.2024.12.039","article-title":"Maintaining first-line therapy plus radiation therapy may prolong progression-free survival and delay second-line therapy for oligoprogressive hepatocellular carcinoma","volume":"122","author":"Leng","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0034","doi-asserted-by":"crossref","first-page":"882","DOI":"10.21037\/hbsn-23-134","article-title":"Efficacy and safety of subsequent radiotherapy in patients with advanced-stage hepatocellular carcinoma treated with immune checkpoint inhibitors","volume":"12","author":"Ning","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0035","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12672-024-01360-y","article-title":"Effectiveness of radiotherapy in delaying treatment changes in primary or secondary immunorefractory oligoprogressive patients: Preliminary results from a single-center study","volume":"15","author":"Zagardo","year":"2024","journal-title":"Discov Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0036","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/vaccines3030597","article-title":"Cancer dormancy: A regulatory role for endogenous immunity in establishing and maintaining the tumor dormant state","volume":"3","author":"Baxevanis","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0037","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1189\/jlb.5A1215-580R","article-title":"Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells","volume":"100","author":"Payne","year":"2016","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ijrobp.2025.12.049_bib0038","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162600009X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162600009X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:55:20Z","timestamp":1773978920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162600009X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S036030162600009X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.049","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Body Radiation Therapy With Continued First-Line PD-1 Inhibitor-based Therapy as a Resistance-Overcoming Strategy in Oligoprogressive Hepatocellular Carcinoma: A Prospective Phase 2 Clinical Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}